Cas:55654-11-0 3-amino-3-hydroxyiminopropanoic acid manufacturer & supplier

Chemical Name:3-amino-3-hydroxyiminopropanoic acid

CAS.NO:55654-11-0

Synonyms:malonic acid-1-amide-1-oxime;Malonsaeure-monoamidoxim;Malonsaeure-1-amid-1-oxim;malonic acid monoamidoxime

Molecular Formula:C₃H₆N₂O₃

Molecular Weight:118.09100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:93.41000

Exact Mass:118.03800

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like malonic acid-1-amide-1-oxime chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,malonic acid monoamidoxime physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,malonic acid-1-amide-1-oxime Use and application,malonic acid monoamidoxime technical grade,usp/ep/jp grade.

Related News: There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space. 3-amino-3-hydroxyiminopropanoic acid manufacturer Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries. 3-amino-3-hydroxyiminopropanoic acid supplier As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 3-amino-3-hydroxyiminopropanoic acid vendor As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 3-amino-3-hydroxyiminopropanoic acid factory Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.